Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 33.25
(-1.77%)
TWD 33.25
(-1.77%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.2 Billion TWD | 100.0% |
| 2022 | 604.54 Million TWD | -19.77% |
| 2021 | 753.55 Million TWD | 17481.73% |
| 2020 | 4.28 Million TWD | -99.52% |
| 2019 | 896.29 Million TWD | 12.24% |
| 2018 | 798.58 Million TWD | -32.9% |
| 2017 | 1.19 Billion TWD | 133.23% |
| 2016 | 510.24 Million TWD | -8.92% |
| 2015 | 560.22 Million TWD | -51.31% |
| 2014 | 1.15 Billion TWD | 26.42% |
| 2013 | 910.23 Million TWD | 16.7% |
| 2012 | 779.96 Million TWD | 333.36% |
| 2011 | 179.98 Million TWD | 157.12% |
| 2010 | 70 Million TWD | -85.71% |
| 2009 | 489.77 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.32 Billion TWD | 9.99% |
| 2024 Q2 | 1 Billion TWD | -24.17% |
| 2023 Q4 | 1.2 Billion TWD | 9.3% |
| 2023 FY | 1.2 Billion TWD | 100.0% |
| 2023 Q1 | 903.28 Million TWD | 49.42% |
| 2023 Q3 | 1.1 Billion TWD | 34.22% |
| 2023 Q2 | 824.16 Million TWD | -8.76% |
| 2022 Q2 | 605.51 Million TWD | -32.3% |
| 2022 Q1 | 894.42 Million TWD | 18.69% |
| 2022 FY | 604.54 Million TWD | -19.77% |
| 2022 Q4 | 604.54 Million TWD | -7.81% |
| 2022 Q3 | 655.76 Million TWD | 8.3% |
| 2021 Q1 | 3.07 Million TWD | -28.21% |
| 2021 FY | 753.55 Million TWD | 17481.73% |
| 2021 Q3 | 774.15 Million TWD | 118.93% |
| 2021 Q4 | 753.55 Million TWD | -2.66% |
| 2021 Q2 | 353.6 Million TWD | 11391.91% |
| 2020 Q3 | 5.02 Million TWD | -10.51% |
| 2020 FY | 4.28 Million TWD | -99.52% |
| 2020 Q1 | 895.05 Million TWD | -0.14% |
| 2020 Q2 | 5.61 Million TWD | -99.37% |
| 2020 Q4 | 4.28 Million TWD | -14.66% |
| 2019 Q3 | 913.21 Million TWD | 5.77% |
| 2019 Q4 | 896.29 Million TWD | -1.85% |
| 2019 FY | 896.29 Million TWD | 12.24% |
| 2019 Q1 | 834.92 Million TWD | 4.55% |
| 2019 Q2 | 863.38 Million TWD | 3.41% |
| 2018 Q1 | 1.05 Billion TWD | -11.25% |
| 2018 Q4 | 798.58 Million TWD | 17.79% |
| 2018 Q3 | 677.97 Million TWD | -34.05% |
| 2018 FY | 798.58 Million TWD | -32.9% |
| 2018 Q2 | 1.02 Billion TWD | -2.67% |
| 2017 Q2 | 510.07 Million TWD | 10.92% |
| 2017 Q4 | 1.19 Billion TWD | 47.16% |
| 2017 FY | 1.19 Billion TWD | 133.23% |
| 2017 Q3 | 808.66 Million TWD | 58.54% |
| 2017 Q1 | 459.87 Million TWD | -9.87% |
| 2016 Q4 | 510.24 Million TWD | -13.64% |
| 2016 FY | 510.24 Million TWD | -8.92% |
| 2016 Q3 | 590.83 Million TWD | 34.31% |
| 2016 Q2 | 439.89 Million TWD | -16.96% |
| 2016 Q1 | 529.73 Million TWD | -5.44% |
| 2015 FY | 560.22 Million TWD | -51.31% |
| 2015 Q2 | 506.52 Million TWD | -5.27% |
| 2015 Q1 | 534.69 Million TWD | -53.53% |
| 2015 Q4 | 560.22 Million TWD | 4.56% |
| 2015 Q3 | 535.77 Million TWD | 5.78% |
| 2014 Q3 | 1.12 Billion TWD | 18.54% |
| 2014 FY | 1.15 Billion TWD | 26.42% |
| 2014 Q4 | 1.15 Billion TWD | 2.55% |
| 2014 Q2 | 946.6 Million TWD | -0.09% |
| 2014 Q1 | 947.47 Million TWD | 4.09% |
| 2013 Q3 | 904.13 Million TWD | 32.01% |
| 2013 Q4 | 910.23 Million TWD | 0.67% |
| 2013 FY | 910.23 Million TWD | 16.7% |
| 2013 Q1 | 747.41 Million TWD | -4.17% |
| 2013 Q2 | 684.9 Million TWD | -8.36% |
| 2012 FY | 779.96 Million TWD | 333.36% |
| 2012 Q2 | 844.98 Million TWD | 322.6% |
| 2012 Q3 | 822.33 Million TWD | -2.68% |
| 2012 Q4 | 779.96 Million TWD | -5.15% |
| 2012 Q1 | 199.94 Million TWD | 11.09% |
| 2011 Q4 | 179.98 Million TWD | -14.27% |
| 2011 Q2 | 70 Million TWD | 600.0% |
| 2011 Q1 | 10 Million TWD | -85.71% |
| 2011 FY | 179.98 Million TWD | 157.12% |
| 2011 Q3 | 209.94 Million TWD | 199.92% |
| 2010 FY | 70 Million TWD | -85.71% |
| 2010 Q4 | 70 Million TWD | 0.0% |
| 2009 FY | 489.77 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 180.83 Million TWD | -568.643% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.94 Billion TWD | 37.835% |
| Panion & Bf Biotech Inc. | 727.83 Million TWD | -66.125% |
| GenMont Biotech Incorporation | 58.3 Million TWD | -1973.701% |
| Abnova (Taiwan) Corporation | 7.7 Million TWD | -15590.54% |
| Adimmune Corporation | 3.14 Billion TWD | 61.525% |
| Tanvex BioPharma, Inc. | 1.73 Billion TWD | 30.181% |
| Polaris Group | 1.19 Billion TWD | -0.925% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 74.32 Million TWD | -1526.726% |
| PELL Bio-Med Technology Co. Ltd. | 172.55 Million TWD | -600.704% |